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Abstract
Coronary artery disease (CAD) is the commonest cause of death. Here, we report an association
analysis in 63,746 CAD cases and 130,681 controls identifying 15 loci reaching genome-wide
significance, taking the number of susceptibility loci for CAD to 46, and a further 104 independent
variants (r2 < 0.2) strongly associated with CAD at a 5% false discovery rate (FDR). Together,
these variants explain approximately 10.6% of CAD heritability. Of the 46 genome-wide
significant lead SNPs, 12 show a significant association with a lipid trait, and 5 show a significant
association with blood pressure, but none is significantly associated with diabetes. Network
analysis with 233 candidate genes (loci at 10% FDR) generated 5 interaction networks comprising
85% of these putative genes involved in CAD. The four most significant pathways mapping to
these networks are linked to lipid metabolism and inflammation, underscoring the causal role of
these activities in the genetic etiology of CAD. Our study provides insights into the genetic basis
of CAD and identifies key biological pathways.
© 2013 Nature America, Inc. All rights reserved.
1A full list of authors and affiliations appears at the end of the paper.
URLs. QVALUE software for FDR analysis, http://genomics.princeton.edu/storeylab/qvalue/; coronary heart disease statistics, http://
www.bhf.org.uk/publications/view-publication.aspx?ps=1002097; top 10 causes of death fact sheet 310, http://www.who.int/
mediacentre/factsheets/fs310/en/index.html; Uppsala Platform, http://molmed.medsci.uu.se/SNP+SEQ+Technology+Platform/
Genotyping.
Accession codes. Summary statistics for the 79,138 SNPs considered in this study for association with CAD (SNPs with stage 1 and
stage 2 data) are available at ftp://ftp.sanger.ac.uk/pub/cardiogramplusc4d/.
Note: Supplementary information is available in the online version of the paper.
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Coronary artery disease and its main complication, myocardial infarction, is the leading
cause of death worldwide. Although, epidemiological studies have identified many risk
factors for CAD, including plasma lipid concentrations, blood pressure, smoking, diabetes
and markers of inflammation, a causal role has been proven only for some (for example,
low-density lipoprotein (LDL) cholesterol and blood pressure), primarily through
randomized clinical trials of drug therapy directed at the risk factor1. Twin and family
studies have documented that a significant proportion (40–50%) of susceptibility to CAD is
heritable (for a review, see ref. 2). Because genotypes are not confounded by environmental
exposures, genetic analysis has the potential to define which risk factors are indeed causal
and to identify pathways and therapeutic targets3,4. To date, genome-wide association
studies (GWAS) have collectively reported a total of 31 loci, associated with CAD risk at
genome-wide significance (P < 5 × 10−8)5-13. However, variants at these loci explain less
than 10% of the heritability of CAD. One likely reason for this is that, given the polygenic
nature of complex traits and the relatively small observed effect sizes of the loci identified,
many genuinely associated variants do not reach the stringent P-value threshold for genome-
wide significance. Indeed, there is increasing evidence that the genetic architecture of
common traits involves a large number of causative alleles with very small effects14.
Addressing this will require the discovery of additional loci while leveraging large-scale
genomic data to identify the molecular pathways underlying the pathogenesis of CAD. Such
discovery is facilitated by building molecular networks, on the basis of DNA, RNA and
protein interactions, which have nodes of known biological function that also show evidence
of association with risk variants for CAD and related metabolic traits.
In the largest GWAS meta-analysis of CAD undertaken to date by the Coronary ARtery
DIsease Genome-wide Replication and Meta-analysis (CARDIoGRAM) Consortium5,
which involved 22,233 cases and 64,762 controls, in addition to loci reported at genome-
wide significance, a linkage disequilibrium (LD)-pruned set of 6,222 variants achieved a
nominal association P value of less than 0.01. Here, we test these 6,222 SNPs in a meta-
analysis of over 190,000 individuals, with the primary aim of identifying additional
susceptibility loci for CAD. To this end, we used the Metabochip array15, which is a custom
iSELECT chip (Illumina) containing 196,725 SNPs, designed to (i) follow-up putative
associations in several cardiometabolic traits, including CAD, and (ii) fine map confirmed
loci for these traits. All SNPs on the array with data in the CARDIoGRAM study were
considered for analysis (79,138 SNPs, of which 6,222 were the replication SNPs and 20,876
were fine-mapping SNPs in the 22 CAD susceptibility loci identified at the time at which the
array was designed; the remaining SNPs were submitted by the other consortia contributing
to the Metabochip array15). In addition, we assess whether the genome-wide significant
CAD risk alleles act through traditional risk factors by considering the available large
GWAS for these traits16-20. Finally, we identify a broader set of SNPs passing a
conservative FDR threshold for association with CAD and use this set to undertake network
analysis to find key biological pathways underlying the pathogenesis of CAD.
RESULTS
Study design
We expanded the CARDIoGRAM discovery data set (22,233 cases and 64,762 controls5,
stage 1) with 34 additional CAD sample collections (stage 2) of European or south Asian
descent comprising 41,513 cases and 65,919 controls (study descriptions and sample
characteristics are given in Supplementary Tables 1a and 2a, respectively) and undertook a
2-stage meta-analysis to test SNPs on the Metabochip array for disease association in a total
of 63,746 cases and 130,681 controls. A further set of 3,630 cases and 11,983 controls from
4 independent studies was used for replication of SNPs that reached 5 × 10−8 < P < 1 × 10−6
in combined stage 1 and 2 analysis (stage 3; Supplementary Tables 1b and 2b). An overview
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of the study design is provided in Supplementary Figure 1. Cases were selected for inclusion
following the standard criteria for CAD and myocardial infarction used in the
CARDIoGRAM study5 (details for the stage 2 and 3 cohorts are given in Supplementary
Table 2). Collections were typed with either the Metabochip array (60% of samples) or
provided GWAS data imputed using HapMap (Supplementary Table 3). We applied
standard quality control criteria to each study and corrected for population stratification if
λGC was ≥1.05 (estimated for samples typed on the Metabochip using 4,310 SNPs
associated with long QT syndrome and located at least 5 Mb away from established CAD
risk loci; Online Methods). Case-control association analyses were adjusted for sex and age.
For the 79,138 SNPs on the Metabochip with both stage 1 and 2 data, we combined (2-
sided) P values from stage 1 with their respective (1-sided) P values for stage 2 using
Fisher’s method (Online Methods). In stage 3, we validated SNPs at 5 × 10−8 < P < 1 × 10−6
and combined evidence across all stages (1– 3) using a sample size–weighted meta-analysis.
Genome-wide significant loci
We first examined the 30 CAD risk loci previously reported in individuals of European
ancestry at genome-wide significance (the ADTRP (C6orf105) locus has been reported only
in Chinese)12 in the stage 2 samples. For the 26 loci in which we could test the known lead
SNP or a suitable proxy (r2 > 0.8), we found highly significant associations in the stage 2
samples (Table 1). Notably, in four of these loci (CDKN2B-AS1, COL4A2, CXCL12 and
APOE), we detected additional SNPs not in LD (r2 < 0.5) with the lead SNP, which also
reached genome-wide significance and were conditionally independent when analyzed with
GCTA software21. The additional SNP in the APOE locus, rs445925 (P = 9.42 × 10−11; r2 =
0.015 with rs207560 in 1000 Genomes Project data), is located near APOC1, a gene
previously suggested to confer risk for CAD22. The r2 value between rs445925 (P = 9.42 ×
10−11; n = 31 studies) and rs7412 (P = 8.86 × 10−4; n = 21 studies), which tags the APOE e2
allele,is 0.588. The LIPA locus also harbors a strong independent signal, which, however,
did not reach genome-wide significance. Findings for the strongest associated variant
available on the Metabochip for the other four loci (MIA3, 7q22, ZNF259-APOA5-APOA1
and ADAMTS7) for which we did not have a good proxy for the previously reported lead
SNP are also given (Table 1). Notably, for ADAMTS7, rs7173743 (r2 = 0.38 with
rs3825807, the published lead SNP) also achieved genome-wide significance.
We next examined the association of the 6,222 SNPs with P < 0.01 in CARDIoGRAM (we
excluded SNPs in all loci listed in Table 1). Distribution of the absolute z scores for these
SNPs in the stage 2 samples showed strong enrichment in positive scores corresponding to
SNPs with directionally consistent signals between stages 1 and 2 under the null
distribution, which is defined by mean = 0 and s.d. = 1 (4,260 SNPs observed versus 3,111
SNPs expected; binomial 2-sided P = 7.5 × 10−187) (Supplementary Fig. 2). In total, 19 loci
showed association at P < 1 × 10−6 in the combined stage 1 and 2 analysis, with 13 of them
reaching genome-wide significance, namely IL6R, APOB, VAMP5-VAMP8-GGCX,
SLC22A4-SLC22A5, ZEB2-AC074093.1, GUCY1A3, KCNK5, LPL, PLG, TRIB1,
ABCG5-ABCG8, FURIN-FES and FLT1 (Table 2; Forest and regional association plots are
given in Supplementary Figs. 3 and 4, respectively). The 6 loci with associations not
reaching P < 5 × 10−8 were further validated (stage 3) in 4 independent studies (3,630 cases
and 11,983 controls; Supplementary Table 1b). Two loci, EDNRA and HDAC9 replicated at
P < 0.05 and reached genome-wide significance in a combined analysis of stages 1-3 (Table
2); findings for those SNPs not meeting the above criteria are shown in Supplementary
Table 4.
Of the newly associated loci reaching genome-wide significance, TRIB1 and ABCG5-
ABCG8 were recently reported to reach study-wide significance (P < 3 × 10−6) in a large
candidate gene (IBC array) study of CAD13. The same study reported rs2706399 in the IL5
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locus, which is located 200,349 bp away from the SNP we detected in the SLC22A4-
SLC22A5 locus (rs273909; Table 2). Although located in the same recombination interval,
these SNPs are not in LD (r2 = 0.02), and conditional analysis in a subset of 85,136 samples
(up to19,200 cases) suggested that the 2 signals are conditionally independent; when
conditioning on rs2706399 (IL5 locus), the P value for rs273909 (SLC22A4 locus) was 5.54
× 10−3 (1.33 × 10−3 initially), whereas the converse conditioning gave a P value of 3.34 ×
10−2 for rs2706399 (IL5; 7.55 × 10−3 initially). We also detected a second signal in the FES
locus (rs2521501; P = 1.31 × 10−9); conditional analysis with rs17514846 and rs2521501 (r2
= 0.43 in 1000 Genomes Project data) showed the two signals not only to be independent but
to also increase in strength upon conditioning (rs17514846 associated at P = 1.07 × 10−25
when conditioned on rs2521501; conversely, the P value for rs2521501 was 9.24 × 10−26).
Subgroup analyses
Genetic risk of CAD could vary by age and gender and could also specifically influence the
risk of its main adverse outcome, myocardial infarction23. We therefore undertook
exploratory association analyses in subgroups partitioned by either gender, age at event
(with individuals of <50 years of age being defined as young cases) or history of myocardial
infarction (Online Methods). For the 46 genome-wide significant CAD risk loci, we
observed no trend for higher odds ratios (ORs) in any of the subgroup analyses
(Supplementary Table 5). However, one new locus reached genome-wide significance in
males and in young CAD cases (rs16986953; P = 1.89 × 10−8 and 1.67 × 10−8, respectively),
which is located in a gene desert (with nearest transcript AK097927), 1.3 Mb away from the
APOB gene. Interaction analysis conducted in a subset of studies (n = 12) where we had
individual-level data provided suggestive evidence of an association with age (P = 0.033)
but not with sex (P = 0.708); further studies are required to confirm this finding.
Wider Metabochip content
In addition to SNPs provided by the CARDIoGRAM Consortium, the Metabochip array
contains a further 113,248 SNPs submitted for a range of cardiometabolic traits15 other than
CAD itself (associated at P > 0.01 with CAD in CARDIoGRAM samples or not tested). For
these SNPs, we did not detect any new locus reaching genome-wide significance in our data
set (including stage 1 and 3 data, when available). In total, therefore, we discovered 15
newly associated loci at genome-wide significance, increasing the total number of genome-
wide significant loci to 45 in individuals of European and south Asian ancestry.
Localizing candidate CAD genes
To identify potential causal CAD-associated genes at the 15 new susceptibility loci
identified in our study, we first analyzed genome-wide expression quantitative trait locus
(eQTL) data in multiple tissues (circulating monocytes, liver, fat, skin, omentum, aortic
media and adventitia, mammary artery and lymphoblastoid cell lines (LCLs)). We found
that the lead SNP or a proxy in high LD (r2 ≥ 0.8) in three of the new loci was associated in
cis with variable expression levels of the GGCX-VAMP8, PLG and FES genes
(Supplementary Table 6). We then assessed allele-specific expression data in monocytes,
fibroblasts and LCLs and found three loci where the lead SNP was associated with an
imbalance in expression of either LPL, GGCX or FES; IL6R showed some evidence of
allele-specific expression in the fibroblast sample (Supplementary Table 6). Finally, we
examined the new CAD risk loci for genes with relevant disease trait associations in mouse
knockout models; six loci harbor a gene for which a mouse knockout model has a relevant
cardiovascular phenotype, namely ABCG8, APOB, GUCY1A3, PLG, LPL and FES
(Supplementary Table 7). PLG is adjacent to LPA, and, although the PLG risk variant
rs4252120[T] was strongly associated with elevated Lp(a) lipoprotein levels (P = 5 × 10−24)
in 3,698 PROCARDIS cases, it was associated with CAD independent of the LPA-linked
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variant at rs3798220. A detailed discussion of the genes in each locus is provided in the
Supplementary Note. Of the 30 previously reported CAD susceptibility loci in individuals of
European and south Asian ancestry, mouse knockout models for the candidate genes PEMT,
APOE, LDLR, COL4A1, LIPA, APOA1-APOA5, PPAP2B and PCSK9 also show
phenotypic characteristics directly relevant to disease (Supplementary Table 7). In total,
approximately a third of the 45 CAD loci contain a known functionally relevant candidate
gene.
Overlap with traditional risk factors
We assessed both the known and new CAD susceptibility loci for overlap of associations
with a number of relevant traits for which summary statistics have been made available:
lipid levels (GLGC)16, blood pressure (ICBPG)17, diabetes (DIAGRAM)18, glucometabolic
traits (fasting insulin and fasting glucose concentrations, HOMA-B (homeostatic model
assessment-β score) and HOMA-IR (insulin resistance); MAGIC)19 and anthropometric
traits (GIANT)20,24. After applying a Bonferroni correction for the 51 independent CAD-
associated alleles tested (44 loci; no data available for rs16986953 and rs2521501), 12 loci
showed evidence of association (P < 1 × 10−4) between the lead CAD risk SNP and 1 or
more plasma lipid trait (total cholesterol, LDL cholesterol, high-density lipoprotein (HDL)
cholesterol and triglyceride concentration) in the expected direction (the CAD risk allele
was associated with higher total cholesterol, LDL cholesterol and triglyceride concentrations
and lower HDL cholesterol concentration). These lead SNPs were most strongly associated
with LDL cholesterol concentration at eight loci (APOB, ABCG5-ABCG8, PCSK9,
SORT1, ABO, LDLR, APOE and LPA), with triglyceride concentration at two loci (TRIB1
and the APOA5 cluster) and with HDL cholesterol concentration at one locus (ANKS1A).
There was near-equivalent association for triglyceride and HDL cholesterol concentrations
at one locus (LPL). All loci except LPA and ANKS1A showed genome-wide significance
for association with a lipid trait. These results underscore the importance of LDL cholesterol
as a causal CAD risk factor (Supplementary Table 8). At the SH2B3 locus, the CAD risk
allele for rs3184504 was associated with both lower LDL cholesterol (P = 1.73 × 10−9) and
HDL cholesterol (P = 4.97 × 10−6) concentration; one likely explanation is the presence of
independent variants for CAD and LDL cholesterol. Two known CAD risk loci (CYP17A1-
NT5C2 and SH2B3) and two of the new CAD susceptibility loci (GUCY1A3 and FES) have
previously been associated with systolic (SBP) and diastolic (DBP) blood pressure17.
Significant evidence for association with DBP was also observed for ZC3HC1
(Supplementary Table 8). In contrast to the results for lipid concentration and blood
pressure, there was no significant association of any of the loci tested with type 2 diabetes
(T2D). Consistent with this observation, none of the assessed glucometabolic traits (fasting
insulin and fasting glucose concentrations, HOMA-B and HOMA-IR) were related to these
CAD variants (at the ANKS1A locus, it was not the CAD risk SNP that was associated with
fasting insulin concentration and HOMA-IR). Suggestive associations (P < 1 × 10−4) with
body mass index (BMI) and waist-hip ratio were observed in the CYP17A1-CNNM2-
NT5C2 and RAI1-PEMT-RASD1 loci, respectively.
Additional suggestive associations
The genome-wide significance threshold, P < 5 × 10−8, we used is the accepted criterion for
reporting individual association signals, as for each experiment it controls the error rate
among common variants to less than 5%. However, SNPs showing suggestive association
with a phenotype but not meeting this genome-wide threshold are likely to include
additional true positive signals in well-powered studies (Supplementary Fig. 1). Such SNPs
may also be informative in predicting CAD risk and in constructing CAD-associated
biological networks. To identify such variants, we undertook an FDR analysis to assess the
proportion of false positive signals in a set of (nominally) significant SNPs25. The
Page 5
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Metabochip array contains both SNPs with priors in terms of association to CAD
(CARDIoGRAM study P < 0.01) and blocks of highly correlated SNPs in fine-mapping
regions. Therefore, to normalize the distribution of SNPs considered for FDR analysis, we
(i) removed all SNPs in the CAD fine-mapping regions and LD-pruned (r2 < 0.2) SNPs in
the non CAD fine-mapping regions and (ii) adjusted the combined P values of all SNPs with
priors in stage 1 (P < 0.01) using fixed-effect inverse variance–weighted meta-analysis P
values for all other SNPs (Online Methods). In addition, we obtained 104 SNPs at an FDR
threshold of 5% and LD threshold of r2 < 0.2 (Supplementary Table 9). The median OR for
CAD for these SNPs was 1.054 (interquartile range of 0.0199) per risk allele
(Supplementary Fig. 5).
On the basis of a heritability estimate of 40% for CAD, the combination of the known and
newly associated SNPs within the 45 susceptibility loci (Tables 1 and 2) explains
approximately 6% of the additive genetic variance of CAD. The addition of the 104 SNPs
from FDR analysis increased the fraction explained to 10.6% (Online Methods).
Network analysis
In contrast to estimating heritability where we want to keep the false positive rate as low as
possible, in network analysis, we want to maximize the representation of potential network
nodes in the gene set used. Thus, to perform network analysis, we selected the top 222 SNPs
defined by the FDR analysis (10% FDR; final P < 6.6 × 10−4) at an LD threshold of r2 ≤ 0.7
and assigned 239 candidate genes on the basis of either eQTL data or physical proximity
(Supplementary Table 10). We mapped 238 of the 239 genes in the Ingenuity Knowledge
Base and considered 233 for network construction (Online Methods) on the basis of
available data on interactions in humans, mice and/or rats (51 genes within the 46 genome-
wide significant loci (set A) and 182 genes within the loci selected at FDR < 10% (set B)).
Including neighboring genes, Ingenuity generated 9 networks comprising 553 nodes; these
included 48 (94.1%) of the genes in set A and 156 (85.7%) of those in set B (Supplementary
Table 10). We obtained 2 overlapping networks: ON1, which included networks 1, 2, 6 and
8, comprising the majority of genes in both sets (33 and 83 in sets A and B, respectively),
and ON2, which included networks 4 and 7 (Supplementary Table 10). The nine networks
were strongly enriched for genes (query set) known to be involved in lipid metabolism (P =
1.48 × 10−9), cellular movement (blood and endothelial cells; P = 1.35 × 10−7) and
processes such as tissue morphology (size and area of atherosclerotic lesion, quantity of
leukocytes, macrophages and smooth muscle cells; P = 9.66 × 10−10) and immune cell
trafficking (migration and adhesion; P = 1.12 × 10−7). As a negative control in the network
analysis, we used a set of 368 genes selected from the least significant SNPs in the FDR
analysis; the resulting networks showed no significant enrichment in relevant molecular
functions and process (results described in detail in the Supplementary Note).
We then assessed how genes in the networks overlap with canonical pathways in the
Ingenuity database. The four most significant canonical pathways represented in these
networks are shown in Figure 1a. The top three pathways, atherosclerosis signaling, liver X
receptor (LXR)/retinoid X receptor (RXR) activation and farnesoid X receptor (FXR)/RXR
activation, all harbor genes involved in lipid metabolism, including ten CAD risk loci
(ABCG5-ABCG8, APOA1, APOA5, APOB, APOE, CXCL12, LDLR, LPA, LPL and
PDGFD). This is in agreement with our finding that 12 CAD risk loci are associated with
lipid levels at P < 1 × 10−4 (Supplementary Table 8). Notably, three of the top four pathways
also contain genes involved in inflammation. In addition to the atherosclerosis signaling and
LXR/RXR activation pathways, the acute phase response signaling (AAPRS) pathway,
which includes four CAD risk loci (APOA1, MRAS, IL6R and PLG), is involved in
inflammation and, more specifically, the rapid inflammatory response that is triggered,
among other factors, by tissue injury. Genes from both the lipid metabolism and
Page 6
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
inflammation-related pathways map to all networks, except network 9, which harbors only
two genes (Supplementary Table 10). As shown for overlapping network ON1
(Supplementary Fig. 6), genes in lipid metabolism and inflammation are interconnected and
include both CAD-associated loci reaching genome-wide significance and candidate loci at
FDR < 10%. Key interactions between CAD susceptibility genes (known, new and the FDR
set) involved in lipid metabolism and inflammation are shown in Figure 1b; macrophages
take up oxidized LDL (ox-LDL) through their cell surface scavenger receptors to form foam
cells. Foam cells secrete proinflammatory cytokines, such as interleukin (IL)-1, IL-6 and
matrix metalloproteinases, which can amplify the local inflammatory response and stimulate
smooth muscle cell proliferation and initial migration toward the lesion26. Regulation of
collagen secretion by smooth muscle cells in the extracellular matrix is regulated by matrix
metalloproteinases. Reduction of collagen in the extracellular matrix will destabilize the
plaque. Both COL4A1 and COL4A2 encode subunits of type IV collagen, which is the
major structural component of basement membranes lining the inner surface of blood
vessels. Metalloproteinases have a role in the maintenance of the extracellular matrix and
remodeling, contributing to the transition of plaques from stable to vulnerable states (Fig.
1b).
DISCUSSION
Here, we report the largest genetic study to date assessing the impact of common variation
on CAD risk. On the basis of analyses involving 63,746 CAD cases and 130,681 controls,
we identified 15 new risk alleles at genome-wide significance, bringing the total number of
confirmed CAD susceptibility loci in individuals of European and south Asian ancestry to
45. We also identified a further set of 104 likely independent (r2 < 0.2) SNPs associated at
an FDR of 5% with ORs between 1.031 and 1.126 per risk allele. In total, we estimate that
these variants explain approximately 10.6% of the additive genetic variance of CAD
(although we note that this may be an overestimate, given that it was not obtained in an
independent sample). Our data also support the presence of additional true signals among
the tested common SNPs that are likely to further contribute in explaining heritability; for
example, the P-value adjustment we applied in the FDR analysis penalized the replication
SNPs.
Among the 45 loci in individuals of European and south Asian ancestry that were confirmed
to be associated with CAD, we found that 12 were significantly associated with the
concentrations of blood lipids (mainly with LDL cholesterol), and 5 were associated with
blood pressure. These data support the known etiological relationships of plasma lipids and
blood pressure with CAD. People with T2D seem to have a 1.5- to 2-fold higher risk of
CAD than those without diabetes27, but none of the 45 risk loci were associated with
diabetes status or with continuous levels of various glucometabolic traits. We note that, for
the binary variable of T2D status, inability to show associations with CAD risk loci may
reflect limited statistical power. The temporal relationship for comorbidity with both
diabetes and CAD is complex: individuals with CAD without diabetes at diagnosis often
subsequently develop T2D28. Furthermore, despite clear benefits in preventing
microvascular disease (for example, retinopathy and nephropathy), intensive glucose control
in diabetics reduces the risk of cardiovascular disease relatively modestly29. However,
before a final conclusion can be reached, as many cohorts contributing to this meta-analysis
focused by design on early disease manifestation or excluded diabetic individuals, a formal
testing of the relationship of T2D and CAD in Mendelian randomization experiments will be
necessary. To this end, the large genetic association data set on CAD assembled here will
also facilitate testing of the causal relationship of other putative risk factors for CAD.
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A desirable clinical goal is to integrate genetic information into a risk score for CAD in an
attempt to provide improved predictive power over traditional risk factors in asymptomatic
subjects, such that preventative measures, where available, can be more appropriately
targeted. Our findings provide an appropriate framework of 153 CAD risk variants (at those
established as susceptibility loci meeting the genome-wide significance threshold and
additional suggestive loci with an FDR of <5%) for assessing a genetic risk score in well-
powered prospective studies to determine whether they are sufficiently informative and
independent predictors to have potential for use in day-to-day practice.
Allowing for inherent limitations in selecting likely candidate genes at each locus, our
network analysis identified lipid metabolism and inflammation as key biological pathways
involved in the genetic pathogenesis of CAD. Indeed, there was significant crosstalk
between the lipid metabolism and inflammation pathways identified (Fig. 1). The emergence
of lipid metabolism as a key pathway provides a positive control for the network and
pathway analysis. On the other hand, this analysis provides strong new evidence at the
molecular level in support of the causal involvement of inflammatory mechanisms in the
pathogenesis of coronary atherosclerosis30. The role of inflammation in atherosclerosis is
well documented in the literature26; for example, risk factors such as fat diet, smoking,
hypertension, hyperglycemia, obesity and insulin resistance can trigger the expression of
adhesion molecules (upregulated by atherogenic lipoproteins such as ox-LDL, very-low-
density lipoprotein (VLDL) and Lp(a) lipoprotein) by endothelial cells, leading to the
attachment of monocytes to the arterial wall. Although our analysis identified as significant
the rapid inflammatory response pathway (mediated by NF-κB, MAPK and JAK-STAT
signaling) that is primarily involved in innate immunity, many of the effector pathways in
innate and adaptive immunity are heavily overlapping, and both are likely to have a role in
CAD pathogenesis26. The five CAD-related networks constitute a useful framework for
further functional and mechanistic studies to elucidate the biological processes underlying
CAD pathogenesis and to investigate gene-environment interactions.
ONLINE METHODS
Meta-analysis and combination of evidence across stages
Analyses were performed in each study (Supplementary Table 1a) to test the following
comparisons: all CAD cases with all controls, adjusted for sex and age; male CAD cases
with male controls, adjusted for age; female CAD cases with female controls, adjusted for
age; early-onset CAD cases with early age of onset (≤50 years) with all CAD controls,
adjusted for sex; late-onset CAD cases (>50 years) with all controls, adjusted for sex; and all
myocardial infarction cases with all controls, adjusted for age and sex. Age was defined as
the recruitment age for controls and the event age for cases. We used the additive genetic
model and fixed-effect inverse variance–weighted meta-analysis. SNPs were excluded from
the meta-analysis if present in <17 GWAS and/or Metabochip or <13 Metabochip stage 2
studies. Heterogeneity was evaluated using the Cochran’s Q and I2 statistics. For SNPs with
non-significant heterogeneity (P for Q > 0.01), we report fixed-effect model results. For
SNPs with significant heterogeneity (P for Q <0.01), we performed an outlier test comparing
the results in each study with the average of all other studies. For outliers (P < 0.01 or no
studies with data), we excluded the most extreme study and repeated the meta-analysis. If no
outliers were detected, but heterogeneity was significant, we used a random-effects model
that was also used for all SNPs with significant heterogeneity in stage 1. In stage 3, we used
a fixed-effect inverse variance-weighted meta-analysis.
The combination of evidence across stage 1 and stage 2 meta-analysis results was performed
using Fisher’s combined P-values method; using two-sided P values from stage 1 and one-
sided P values from stage 2 for all SNPs with consistent direction of effect across the two
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stages. We estimated the stage 1 and 2 combined effect sizes for SNPs in the known loci
using a fixed-effect inverse variance–weighted meta-analysis. The combination of evidence
across stages 1–3 for the replication effort was performed using a sample size–weighted
meta-analysis for the selected SNPs. All participants gave written consent for participation
in genetic studies, and the protocol of each study was approved by the corresponding local
research ethics committee or institutional review board.
False discovery rate
FDR control is an alternative approach to experiment-wise error rate control that allows for
statistical multiple testing; identifying as many significantly associated SNPs as possible
with a tolerable false positive burden. FDR analysis is useful for selecting extended panels
of SNPs (and genes) for experiments on the basis of multiple signals (for example, pathway
or network analyses) that are robust to contamination by a small number of false positive
signals. However, given the specific design of the Metabochip array to include selected
SNPs (for replication) with significant P values and several high-density regions (for fine
mapping) associated with CAD and the other cardiometabolic traits, the number of SNPs
significantly associated with CAD, as well as high LD, could bias the FDR analysis.
Therefore, we excluded from the 79,138 SNPs with available stage 1 and 2 data all SNPs
falling in a high-density region associated with CAD (Tables 1 and 2), as well as CAD risk
SNPs associated at P < 5 × 10−8. Furthermore, we performed an LD-based SNP pruning of
the remaining high-density regions (r2 < 0.2). In total, 54,806 SNPs were included in the
FDR analysis.
We combined stage 1 and 2 data as an inverse variance–weighted average, and P values
were calculated by Wald test. SNPs selected because their stage 1 P values were below 0.01
had their combined P values adjusted. If p0 is the P value used as the criterion for selection
in stage 1, z12 is the standardized test statistic obtained by combining the stages (arbitrarily
assumed to be positive) and s1 and s2 are the standard errors for the two stages, then the
adjusted P value is the sum of two integrals representing the two tails in which the stage 1
result might fall. The first is:
and the second has the same form but is integrated from −∞ to Φ−1(p0/2), where Φ is the
cumulative normal function. To test the adjusted P values, a simulation was performed in
which null SNPs were generated and selected in stage 1 on the basis of their P values. These
were combined with random second-stage data simulated again assuming a null effect. The
adjusted P values had the expected uniform distribution between zero and one, suitable for
use in the FDR analysis.
FDR analysis was performed using QVALUE software. A natural cubic spline (with 4
degrees of freedom) was fitted to provide a smoothed estimate of the proportion of null P
values ( ). A density histogram of the P values for the 54,806 SNPs is shown in
Supplementary Figure 7. At FDR = 0.05, we obtained 138 SNPs that were combined with 73
independent SNPs from fine-mapping regions associated with CAD. The selection included
the SNP with the lowest combined P value per fine-mapping region and all SNPs within
these regions that met the 5% FDR criterion in a separate analysis and were unlinked (r2 <
0.2). Finally, all SNPs reported in Tables 1 and 2 were added to the set of 211 SNPs (5%
FDR results and CAD fine-mapped regions), resulting in 153 independent SNPs (104
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identified through the FDR analysis) at r2 < 0.2, which were used for heritability
calculations (Supplementary Table 9).
Heritability
Heritability estimates were calculated locus by locus using the multifactorial liability
threshold model based on OR estimates that assume that the lead SNP at a locus accurately
tags the disease-causing variant, as described in ref. 12. The calculations are based on a
disease prevalence estimate of 5% and an estimate of 40% for the total heritability of
coronary disease.
Expression analyses
We interrogated the 16 new (or proxy; r2 > 0.8) CAD risk SNPs for cis eQTL expression in
multiple tissues: the ASAP study31 used tissue biopsies taken from patients undergoing
carotid endartectomy (plaque n = 117) or valve surgery (liver n = 152, aorta media n = 117,
aorta adventitia n = 103 and mammary artery n = 88). Expression data were generated using
the Affymetrix HG-U133 plus 2.0 array (plaque) or the Affymetrix ST1.0 Exon array (liver,
aorta and mammary artery); in the MuTHER study32, RNA levels were measured in LCLs
(n = 826), skin (n = 705) and fat biopsies (n = 825) from 850 female twins (one-third
monozygotic and two-thirds dizygotic) from the TwinsUK resource using the Illumina
HumanHT-12v3 array. We assessed genotype with gene expression associations, using an
additive linear model (within a 1-Mb window); in Cardiogenics5, monocytes and
macrophages were collected from healthy subjects and individuals with CAD, and RNA was
profiled with the Illumina Human Ref-8 array. eQTL analysis was undertaken in 459 healthy
individuals from Cambridge, UK, using an additive linear model (1-Mb window); in the
Massachusetts General Hospital study33 of liver, omentum and subcutaneous adipose tissue
among subjects undergoing Roux-en-Y gastric bypass surgery, eQTL analysis was
performed with a linear regression model using a 1-Mb window.
In loci with significant cis-eQTL signal(s) (P < 1 × 10−4), we also identified the most
strongly associated cis-eQTL SNP (eSNP) for the corresponding transcript and then
performed conditional analyses, including in the regression model, with either the lead eSNP
or the lead CAD-associated SNP. On the basis of the conditional analysis, we determined
whether the same variant underlies both gene expression regulation and disease.
Finally, we interrogated the lead SNPs in the 16 new CAD susceptibility loci for allelic
expression imbalance effects in LCLs, fibroblasts and monocytes (n = 188; Cardiogenics),
as described in ref. 34.
Network analysis
Genes for network analysis were selected using 310 SNPs (88 SNPs in known and new
CAD risk loci and 222 SNPs at FDR <10% and LD pruned to r2 ≤ 0.7). We first selected
genes with an eQTL (P ≤ 1 × 10−6) and then on the basis of physical proximity (included
overlapping genes on opposite strands or at equal distance from the SNP; genes were
considered within a 40-kb window centered on the SNP). Spliced ESTs and putative
transcripts were not included. Network analysis was performed using the Ingenuity Pathway
Analysis software tool (IPA; Ingenuity Systems). We considered molecules and/or
relationships available in The IPA Knowledge Base for human, mouse or rat and set the
confidence filter to experimentally observed or high (predicted). Networks were generated
with a maximum size of 70 genes, allowing up to 10 networks. Molecules in the query set
with recorded interactions were ‘eligible’ for network construction using the IPA algorithm.
Networks were ranked according to their degree of relevance to the eligible molecules in the
query data set. The score takes into account the number of eligible molecules in the network
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and its size, as well as the total number of eligible molecules analyzed and the total number
of molecules in the Ingenuity Knowledge Base that could potentially be included in the
networks. The network score is based on the hypergeometric distribution and is calculated
by right-tailed Fisher’s exact test. The significance P value associated with enrichment of
functional processes was calculated using the right-tailed Fisher’s exact test by considering
the number of query molecules that participate in that function and the total number of
molecules that are known to be associated with that function in the Ingenuity Knowledge
Base.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank the personnel of the Wellcome Trust Sanger Institute (WTSI) Genotyping Facility, in particular S.
Edkins, for supervising the genotyping of the AMC-PAS, Cardiogenics, GLACIER, MORGAM, PROMIS,
THISEAS, and WTCCC cohorts.
AMC-PAS/SANQUIN.
We thank A.A. Soussan for technical assistance.
We thank personnel from the Estonian Genome Center of the University of Tartu (EGCUT) and the Estonian
Biocentre, especially M. Hass and V. Soo, for data generation.
FINCAVAS.
We thank the staff of the Department of Clinical Physiology for collecting the exercise test data.
The GLACIER Study.
The GLACIER study is a nested study within the Northern Sweden Health and Disease Study; phenotyping was
conducted as part of the Västerbotten Intervention Project.
We thank the participants and the investigators from these studies for their valuable contributions, with specific
thanks to L. Weinehall, Å. Agren, K. Enquist and T. Johansson.
GoDARTS Dundee.
We are grateful to all the participants who took part in this study, to the general practitioners, to the Scottish School
of Primary Care for their help in recruiting the participants and to the whole team, which includes interviewers,
computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and
nurses. We acknowledge the support of the Health Informatics Centre at the University of Dundee in managing and
supplying the anonymized data and National Health Service (NHS) Tayside, the original data owner.
Heart Protection Study.
The study was designed and conducted by the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU)
at the University of Oxford. Genotyping was supported by a grant to Oxford University and Centre National de
Genotypage (CNG) from Merck. The funders had no role in the design of the study or in the data collection or
analysis. We especially acknowledge the participants in the study, the Steering Committee and our collaborators.
J.C.H. acknowledges support from the British Heart Foundation (BHF) Centre of Research Excellence.
LOLIPOP.
We thank the participants and research staff who made the study possible.
MORGAM study.
We thank the contributing sites and key personnel, as detailed below.
Page 11
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Finland: We thank FINRISK, National Institute for Health and Welfare, Helsinki: V.S. (principal investigator), A.
Juolevi, E. Vartiainen and P. Jousilahti; Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study,
National Institute for Health and Welfare, Helsinki: J. Virtamo (principal investigator) and H. Kilpeläinen; the
MORGAM Data Centre, National Institute for Health and Welfare, Helsinki: K. Kuulasmaa (responsible person),
Z. Cepaitis, A. Haukijärvi, B. Joseph, J. Karvanen, S. Kulathinal, M. Niemelä and O. Saarela; and the MORGAM
Central Laboratory, National Institute for Health and Welfare, Helsinki: M.P. (responsible person), P. Laiho and M.
Sauramo.
France: We thank the National Coordinating Centre, National Institute of Health and Medical Research (U258),
Paris: P. Ducimetière (national coordinator) and A. Bingham; Prospective Epidemiological Study of Myocardial
Infarction (PRIME)/Strasbourg, Department of Epidemiology and Public Health, EA 3430, University of
Strasbourg, Faculty of Medicine, Strasbourg: D. Arveiler (principal investigator), B. Haas and A. Wagner; PRIME/
Toulouse, Department of Epidemiology, Toulouse University School of Medicine, Toulouse: J.F. (principal
investigator), J.-B. Ruidavets, V. Bongard, D. Deckers, C. Saulet and S. Barrere; PRIME/Lille, Department of
Epidemiology and Public Health, INSERM U744-Université Lille Nord de France-Institut Pasteur de Lille, Lille: P.
Amouyel (principal investigator), M. Montaye, B. Lemaire, S. Beauchant, D. Cottel, C. Graux, N. Marecaux, C.
Steclebout and S. Szeremeta; and the MORGAM Laboratory, INSERM U937, Paris: F.C. (responsible person), L.
Tiret and V. Nicaud.
Italy: We thank Centro Ricerche EPIMED-Epidemiologia e Medicina Preventiva, Dipartimento di Medicina Clinica
e Sperimentale; Università dell’ Insubria, Varese: M.M.F. (principal investigator) and G. Veronesi; and Research
Centre on Public Health, University of Milano-Bicocca, Monza: G. Cesana.
UK: We thank PRIME/Belfast, Queen’s University Belfast, Belfast: F.K. (principal investigator), A.E. (former
principal investigator), J. Yarnell and E. Gardner; and the MORGAM Coordinating Centre, Queen’s University
Belfast, Belfast: A.E. (MORGAM coordinator), S. Cashman and F.K. MORGAM management group: A.E. (chair),
S.S.B., F.C., M.M.F., K. Kuulasmaa, A. Palotie, M.P., A.P., V.S., H. Tunstall-Pedoe and P.G. Wiklund. Previous
members: K. Asplund, L. Peltonen, D. Shields and B. Stegmayr. The PRIME Study is organized under an
agreement between INSERM and the Merck, Sharpe and Dohme-Chibret Laboratory, with the following
participating laboratories: The Strasbourg MONICA Project, Laboratoire d’Epidémiologie et de Santé Publique,
and the Université de Strasbourg, Strasbourg, France (D. Arveiler and B. Haas); The Toulouse MONICA Project,
UMR INSERM 1027, and the Department of Epidemiology, Toulouse University School of Medicine, Université
Paul Sabatier, Toulouse, France (J.F. and J.-B. Ruidavets); The Lille MONICA Project, INSERM U744, Institut
Pasteur de Lille and Université Lille Nord de France, Lille, France (P. Amouyel and M. Montaye); The Department
of Epidemiology and Public Health, Queen’s University, Belfast, Belfast, UK (A.E., J. Yarnell and F.K.); The
Department of Atherosclerosis, INSERM U545, Institut Pasteur de Lille, Faculté de Médecine and Université Lille
Nord de France, Lille, France (G. Luc and J.-M. Bard); The Laboratory of Haematology, INSERM U626, and
Hôpital La Timone, Marseille, France (I. Juhan-Vague and P. Morange); The Laboratory of Endocrinology,
INSERM U563, Toulouse, France (B. Perret); The Vitamin Research Unit, The University of Bern, Bern,
Switzerland (F. Gey); The Nutrition and Metabolism Group, Centre for Public Health, Queen’s University Belfast,
Belfast, UK (J. Woodside and I. Young); The DNA Bank, INSERM/Université Pierre et Marie Curie (UPMC),
Paris Université Unite Mixte de Recherche (UMRS) 937, Paris (F.C.); The Coordinating Centre, Institut Fédératif
de Recherche Santé Publique (IFR 69), Villejuif, France (P. Ducimetière); and INSERM U970, Villejuif, France,
and University Paris V, Paris Cardiovascular Research Centre (PAARC), Paris (A. Bingham).
PIVUS/Swedish Twin Registry.
We thank the SNP&SEQ Technology Platform in Uppsala (see URLs) for genotyping, in particular T. Axelsson,
A.-C. Wiman and C. Pöntinen for excellent assistance.
Ulm (EMIL).
We thank the Centre of Excellence Baden-Wuerttemberg Metabolic Disorders.
WTCCC.
We thank the BHF Family Heart Study Research Group for the collection of the cases.
Appendix
The authors of this paper are:
Panos Deloukas1,126, Stavroula Kanoni1,126, Christina Willenborg2,126, Martin Farrall3,4,126,
Themistocles L Assimes5,126, John R Thompson6,126, Erik Ingelsson7,126, Danish
Page 12
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Saleheen8-10,126, Jeanette Erdmann2,126, Benjamin A Goldstein5, Kathleen Stirrups1, Inke R
König11, Jean-Baptiste Cazier4, Åsa Johansson12, Alistair S Hall13, Jong-Young Lee14,
Cristen J Willer15,16, John C Chambers17, Tõnu Esko18,19, Lasse Folkersen20,21, Anuj
Goel3,4, Elin Grundberg22, Aki S Havulinna23, Weang K Ho10, Jemma C Hopewell24,25,
Niclas Eriksson12, Marcus E Kleber26,27, Kati Kristiansson23, Per Lundmark28, Leo-Pekka
Lyytikäinen29,30, Suzanne Rafelt31, Dmitry Shungin32-34, Rona J Strawbridge20,21, Gudmar
Thorleifsson35, Emmi Tikkanen36,37, Natalie Van Zuydam38, Benjamin F Voight39, Lindsay
L Waite40, Weihua Zhang17, Andreas Ziegler11, Devin Absher40, David Altshuler41-44,
Anthony J Balmforth45, Inês Barroso1,46, Peter S Braund31,47, Christof Burgdorf48, Simone
Claudi-Boehm49, David Cox50, Maria Dimitriou51, Ron Do41,43, DIAGRAM Consortium52,
CARDIOGENICS Consortium52, Alex S F Doney38, NourEddine El Mokhtari53, Per
Eriksson20,21, Krista Fischer18, Pierre Fontanillas41, Anders Franco-Cereceda54, Bruna
Gigante55, Leif Groop56, Stefan Gustafsson7, Jörg Hager57, Göran Hallmans58, Bok-Ghee
Han14, Sarah E Hunt1, Hyun M Kang59, Thomas Illig60, Thorsten Kessler48, Joshua W
Knowles5, Genovefa Kolovou61, Johanna Kuusisto62, Claudia Langenberg63, Cordelia
Langford1, Karin Leander55, Marja-Liisa Lokki64, Anders Lundmark28, Mark I
McCarthy3,65,66, Christa Meisinger67, Olle Melander56, Evelin Mihailov19, Seraya
Maouche68, Andrew D Morris38, Martina Müller-Nurasyid69-72, MuTHER Consortium52,
Kjell Nikus73, John F Peden3, N William Rayner3, Asif Rasheed9, Silke Rosinger74, Diana
Rubin53, Moritz P Rumpf48, Arne Schäfer75, Mohan Sivananthan76,77, Ci Song7, Alexandre
F R Stewart78,79, Sian-Tsung Tan80, Gudmundur Thorgeirsson81,82, C Ellen van der
Schoot83, Peter J Wagner36,37, Wellcome Trust Case Control Consortium52, George A
Wells78,79, Philipp S Wild84,85, Tsun-Po Yang1, Philippe Amouyel86, Dominique
Arveiler87, Hanneke Basart88, Michael Boehnke59, Eric Boerwinkle89, Paolo Brambilla90,
Francois Cambien68, Adrienne L Cupples91,92, Ulf de Faire55, Abbas Dehghan93, Patrick
Diemert94, Stephen E Epstein95, Alun Evans96, Marco M Ferrario97, Jean Ferrières98,
Dominique Gauguier3,99, Alan S Go100, Alison H Goodall31,47, Villi Gudnason81,101,
Stanley L Hazen102, Hilma Holm35, Carlos Iribarren100, Yangsoo Jang103, Mika
Kähönen104, Frank Kee105, Hyo-Soo Kim106, Norman Klopp60, Wolfgang Koenig107,
Wolfgang Kratzer108, Kari Kuulasmaa23, Markku Laakso62, Reijo Laaksonen108, Ji-Young
Lee14, Lars Lind28, Willem H Ouwehand1,109,110, Sarah Parish24,25, Jeong E Park111, Nancy
L Pedersen7, Annette Peters67,112, Thomas Quertermous5, Daniel J Rader113, Veikko
Salomaa23, Eric Schadt114, Svati H Shah115,116, Juha Sinisalo117, Klaus Stark118, Kari
Stefansson35,81, David-Alexandre Trégouët68, Jarmo Virtamo23, Lars Wallentin12, Nicholas
Wareham63, Martina E Zimmermann118, Markku S Nieminen117, Christian
Hengstenberg118, Manjinder S Sandhu1,63, Tomi Pastinen119, Ann-Christine Syvänen28, G
Kees Hovingh88, George Dedoussis51, Paul W Franks32-34,120, Terho Lehtimäki29,30,
Andres Metspalu18,19, Pierre A Zalloua121, Agneta Siegbahn12, Stefan Schreiber75, Samuli
Ripatti1,37, Stefan S Blankenberg94, Markus Perola23, Robert Clarke24,25, Bernhard O
Boehm74, Christopher O’Donnell93, Muredach P Reilly122,126, Winfried März26,123, Rory
Collins24,25,126, Sekar Kathiresan41,124,125,126, Anders Hamsten20,21,126, Jaspal S
Kooner80,126, Unnur Thorsteinsdottir35,81,126, John Danesh9,126, Colin N A Palmer38,126,
Robert Roberts78,79,126, Hugh Watkins3,4,126, Heribert Schunkert48,126 & Nilesh J
Samani31,47,126
1Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK. 2Institut für Integrative und
Experimentelle Genomik, Universität zu Lübeck, Lübeck, Germany. 3Wellcome Trust
Centre for Human Genetics, University of Oxford, Oxford, UK. 4Cardiovascular Medicine,
Radcliffe Department of Medicine, University of Oxford, Oxford, UK. 5Department of
Medicine, Stanford University School of Medicine, Stanford, California, USA. 6Department
of Health Sciences, University of Leicester, Leicester, UK. 7Department of Medical
Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 8Center for Non-
Communicable Diseases, Karachi, Pakistan. 9Department of Public Health and Primary
Page 13
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Care, University of Cambridge, Cambridge, UK. 10Department of Medicine, University of
Pennsylvania, Philadelphia, Pennsylvania, USA. 11Institut für Medizinische Biometrie und
Statistik, Universität zu Lübeck, Lübeck, Germany. 12Uppsala Clinical Research Center,
Uppsala University, Uppsala, Sweden. 13Division of Cardiovascular and Neuronal
Remodelling, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of
Genetics, Health and Therapeutics, University of Leeds, Leeds, UK. 14Center for Genome
Science, Korea National Institute of Health, Korea Center for Disease Control and
Prevention, Yeonje-ri, Chungwon-gun, Korea. 15Division of Cardiovascular Medicine,
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan,
USA. 16Department of Human Genetics, University of Michigan, Ann Arbor, Michigan,
USA. 17Department of Epidemiology and Biostatistics, Imperial College London, London,
UK. 18Estonian Genome Center, University of Tartu, Tartu, Estonia. 19Institute of
Molecular and Cell Biology, University of Tartu, Tartu, Estonia. 20Atherosclerosis Research
Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. 21Center for
Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden. 22Department of
Twin Research and Genetic Epidemiology, King’s College London, London,
UK. 23Department of Chronic Disease Prevention, National Institute for Health and Welfare,
Helsinki, Finland. 24Clinical Trial Service Unit, University of Oxford, Oxford,
UK. 25Epidemiological Studies Unit, University of Oxford, Oxford, UK. 26Mannheim
Institute of Public Health, Social and Preventive Medicine, Medical Faculty of Mannheim,
University of Heidelberg, Mannheim, Germany. 27Ludwigshafen Risk and Cardiovascular
Health (LURIC) Study, Freiburg, Germany. 28Department of Medical Sciences, Uppsala
University, Uppsala, Sweden. 29Department of Clinical Chemistry, Fimlab Laboratories,
Tampere University Hospital, Tampere, Finland. 30Department of Clinical Chemistry,
University of Tampere School of Medicine, Tampere, Finland. 31Department of
Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester,
UK. 32Genetic & Molecular Epidemiology Unit, Department of Clinical Sciences, Lund
University Diabetes Center, Skåne University Hospital, Malmö, Sweden. 33Department of
Public Health & Clinical Medicine, Genetic Epidemiology & Clinical Research Group,
Section for Medicine, Umeå University, Umeå, Sweden. 34Department of Odontology,
Umeå University, Umeå, Sweden. 35deCODE Genetics, Reykjavik, Iceland. 36Institute for
Molecular Medicine FIMM, University of Helsinki, Helsinki, Finland. 37Public Health
Genomics Unit, National Institute for Health and Welfare, Helsinki, Finland. 38Medical
Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee,
UK. 39Department of Pharmacology, University of Pennsylvania, Philadelphia,
Pennsylvania, USA. 40HudsonAlpha Institute for Biotechnology, Huntsville, Alabama,
USA. 41Broad Institute of Harvard and MIT, Cambridge, Massachusetts,
USA. 42Department of Molecular Biology, Massachusetts General Hospital, Boston,
Massachusetts, USA. 43Center for Human Genetic Research, Massachusetts General
Hospital, Boston, Massachusetts, USA. 44Department of Genetics, Harvard Medical School,
Boston, Massachusetts, USA. 45Division of Cardiovascular and Diabetes Research,
Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Genetics, Health and
Therapeutics, University of Leeds, Leeds, UK. 46University of Cambridge Metabolic
Research Laboratories, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge,
UK. 47National Institute for Health Research (NIHR) Leicester Cardiovascular Biomedical
Research Unit, Glenfield Hospital, Leicester, UK. 48Deutsches Herzzentrum München,
Technische Universität München, Munich, Germany. 49Practice of Gynecology, Ulm
University Medical Centre, Ulm, Germany. 50Biotherapeutics and Bioinnovation Center,
Pfizer, South San Francisco, California, USA. 51Department of Dietetics-Nutrition,
Harokopio University, Athens, Greece. 52A list of members and affiliations appears in the
supplementary Note. 53Klinik für Innere Medizin, Kreiskrankenhaus Rendsburg, Rendsburg,
Germany. 54Cardiothoracic Surgery Unit, Department of Molecular Medicine and Surgery,
Karolinska Institutet, Stockholm, Sweden. 55Division of Cardiovascular Epidemiology,
Page 14
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Institute of Environmental Medicine, Karolinska Institutet, Stockholm,
Sweden. 56Department of Clinical Sciences, Diabetes and Endocrinology, Lund University,
University Hospital Malmö, Malmö, Sweden. 57Commissariat à l’Energie Atomique (CEA)-
Genomics Institute, National Genotyping Centre, Paris, France. 58Department of Public
Health & Clinical Medicine, Section for Nutritional Research, Umeå University, Umeå,
Sweden. 59Department of Biostatistics, Center for Statistical Genetics, University of
Michigan, Ann Arbor, Michigan, USA. 60Hannover Unified Biobank, Hannover Medical
School, Hannover, Germany. 61First Cardiology Department, Onassis Cardiac Surgery
Center 356, Athens, Greece. 62Department of Medicine, University of Eastern Finland and
Kuopio University Hospital, Kuopio, Finland. 63Medical Research Council (MRC)
Epidemiology Unit, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge,
UK. 64Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki,
Finland. 65Oxford Centre for Diabetes, Endocrinology and Metabolism, University of
Oxford, Oxford, UK. 66Oxford NIHR Biomedical Research Centre, Churchill Hospital,
Oxford, UK. 67Institute of Epidemiology II, Helmholtz Zentrum München-German
Research Center for Environmental Health, Neuherberg, Germany. 68Institut National de la
Santé et la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) S937,
Institute for Cardiometabolism and Nutrition (ICAN), Pierre and Marie Curie (Paris 6)
University, Paris, France. 69Department of Medicine I, University Hospital Grosshadern,
Ludwig-Maximilians-Universität, Munich, Germany. 70Chair of Epidemiology, Institute of
Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität,
Munich, Germany. 71Chair of Genetic Epidemiology, Institute of Medical Informatics,
Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich,
Germany. 72Institute of Genetic Epidemiology, Helmholtz Zentrum München-German
Research Center for Environmental Health, Neuherberg, Germany. 73Heart Centre,
Department of Cardiology, Tampere University Hospital, Tampere, Finland. 74Division of
Endocrinology and Diabetes, Department of Internal Medicine, Ulm University Medical
Centre, Ulm, Germany. 75Institut für Klinische Molekularbiologie, Christian-Albrechts
Universität, Kiel, Germany. 76Division of Epidemiology, Multidisciplinary Cardiovascular
Research Centre (MCRC) University of Leeds, Leeds, UK. 77Leeds Institute of Genetics,
Health and Therapeutics, University of Leeds, Leeds, UK. 78University of Ottawa Heart
Institute, Cardiovascular Research Methods Centre Ontario, Ottawa, Ontario,
Canada. 79Ruddy Canadian Cardiovascular Genetics Centre, Ottawa, Ontario,
Canada. 80National Heart and Lung Institute (NHLI), Imperial College London,
Hammersmith Hospital, London, UK. 81Faculty of Medicine, University of Iceland,
Reykjavik, Iceland. 82Department of Medicine, Landspitali University Hospital, Reykjavik,
Iceland. 83Department of Experimental Immunohematology, Sanquin, Amsterdam, The
Netherlands. 84Center for Thrombosis and Hemostasis, University Medical Center Mainz,
Johannes Gutenberg University Mainz, Mainz, Germany. 85Department of Medicine 2,
University Medical Center Mainz, Johannes Gutenberg University Mainz, Mainz,
Germany. 86Institut Pasteur de Lille, INSERM U744, Université Lille Nord de France, Lille,
France. 87Department of Epidemiology and Public Health, EA3430, University of
Strasbourg, Strasbourg, France. 88Department of Vascular Medicine, Academic Medical
Center, Amsterdam, The Netherlands. 89Human Genetics Center, University of Texas
Health Science Center, Houston, Texas, USA. 90Department of Experimental Medicine,
University of Milano-Bicocca, Monza, Italy. 91Department of Biostatistics, Boston
University School of Public Health, Boston, Massachusetts, USA. 92National Heart, Lung,
and Blood Institute’s Framingham Heart Study, Framingham, Massachusetts,
USA. 93Department of Epidemiology, Erasmus Medical Center, Rotterdam, The
Netherlands. 94Clinic for General and Interventional Cardiology, University Heart Center
Hamburg, Hamburg, Germany. 95Cardiovascular Research Institute, Washington Hospital
Center, Washington, DC, USA. 96Centre for Public Health, The Queen’s University of
Belfast, Belfast, UK. 97Research Centre for Epidemiology and Preventive Medicine
Page 15
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(EPIMED), Department of Clinical and Experimental Medicine, University of Insubria,
Varese, Italy. 98Department of Cardiology, Toulouse University School of Medicine,
Rangueil Hospital, Toulouse, France. 99INSERM UMR S872, Cordeliers Research Centre,
Paris, France. 100Division of Research, Kaiser Permanente Northern California, Oakland,
California, USA. 101Icelandic Heart Association, Kopavogur, Iceland. 102Lerner Research
Institute, Cleveland Clinic, Cleveland, Ohio, USA. 103Cardiology Division, Department of
Internal Medicine, Cardiovascular Genome Center, Yonsei University, Seoul,
Korea. 104Department of Clinical Physiology, Tampere University Hospital and University
of Tampere, Tampere, Finland. 105UK Clinical Research Collaboration (UKCRC) Centre of
Excellence for Public Health (Northern Ireland), Queen’s University of Belfast, Belfast,
UK. 106Department of Internal Medicine, Cardiovascular Center, Seoul National University
Hospital, Seoul, Korea. 107Department of Internal Medicine II-Cardiology, Ulm University
Medical Center, Ulm, Germany. 108Science Center, Tampere University Hospital, Tampere,
Finland. 109Department of Haematology, University of Cambridge, Cambridge,
UK. 110National Health Service (NHS) Blood and Transplant, Cambridge, UK. 111Division
of Cardiology, Samsung Medical Center, Seoul, Korea. 112Munich Heart Alliance, Munich,
Germany. 113Division of Translational Medicine and Human Genetics, Department of
Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia,
Pennsylvania, USA. 114Institute for Genomics and Multiscale Biology, Department of
Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York,
USA. 115Center for Human Genetics, Department of Medicine, Duke University Medical
Center, Durham, North Carolina, USA. 116Division of Cardiology, Department of Medicine,
Duke University Medical Center, Durham, North Carolina, USA. 117Division of Cardiology,
Department of Medicine, Helsinki University Central Hospital (HUCH), Helsinki,
Finland. 118Klinik und Poliklinik für Innere Medizin II, Regensburg,
Germany. 119Department of Human Genetics, McGill University, Montréal, Québec,
Canada. 120Department of Nutrition, Harvard School of Public Health, Boston,
Massachusetts, USA. 121Lebanese American University, Chouran, Beirut,
Lebanon. 122Cardiovascular Institute, Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, Pennsylvania, USA. 123Synlab Academy, Mannheim,
Germany. 124Cardiology Division, Center for Human Genetic Research, Massachusetts
General Hospital and Harvard Medical School, Boston, Massachusetts,
USA. 125Cardiovascular Research Center, Massachusetts General Hospital and Harvard
Medical School, Boston, Massachusetts, USA. 126These authors contributed equally to this
work. Correspondence should be addressed to P. Deloukas (panos@sanger.ac.uk) or N.J.S.
(njs@leicester.ac.uk).
References
1. Berry JD, et al. Lifetime risks of cardiovascular disease. N. Engl. J. Med. 2012; 366:321–329.
[PubMed: 22276822]
2. Peden JF, Farrall M. Thirty-five common variants for coronary artery disease: the fruits of much
collaborative labour. Hum. Mol. Genet. 2011; 20:R2, R198–R205. [PubMed: 21531790]
3. Kingsmore SF, Lindquist IE, Mudge J, Gessler DD, Beavis WD. Genome-wide association studies:
progress and potential for drug discovery and development. Nat. Rev. Drug Discov. 2008; 7:221–
230. [PubMed: 18274536]
4. Stein EA, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med.
2012; 366:1108–1118. [PubMed: 22435370]
5. Schunkert H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary
artery disease. Nat. Genet. 2011; 43:333–338. [PubMed: 21378990]
6. Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide association study in
Europeans and South Asians identifies five new loci for coronary artery disease. Nat. Genet. 2011;
43:339–344. [PubMed: 21378988]
Page 16
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
7. Clarke R, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N.
Engl. J. Med. 2009; 361:2518–2528. [PubMed: 20032323]
8. Samani NJ, et al. Genomewide association analysis of coronary artery disease. N. Engl. J. Med.
2007; 357:443–453. [PubMed: 17634449]
9. Erdmann J, et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat.
Genet. 2009; 41:280–282. [PubMed: 19198612]
10. Kathiresan S, et al. Genome-wide association of early-onset myocardial infarction with single
nucleotide polymorphisms and copy number variants. Nat. Genet. 2009; 41:334–341. [PubMed:
19198609]
11. Soranzo N, et al. A genome-wide meta-analysis identifies 22 loci associated with eight
hematological parameters in the HaemGen consortium. Nat. Genet. 2009; 41:1182–1190.
[PubMed: 19820697]
12. Wang F, et al. Genome-wide association identifies a susceptibility locus for coronary artery disease
in the Chinese Han population. Nat. Genet. 2011; 43:345–349. [PubMed: 21378986]
13. The IBC 50K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for
coronary artery disease. PLoS Genet. 2011; 7:e1002260. [PubMed: 21966275]
14. Yang J, et al. Genome partitioning of genetic variation for complex traits using common SNPs.
Nat. Genet. 2011; 43:519–525. [PubMed: 21552263]
15. Voight BF, et al. The Metabochip, a custom genotyping array for genetic studies of metabolic,
cardiovascular, and anthropometric traits. PLoS Genet. 2012; 8:e1002793. [PubMed: 22876189]
16. Teslovich TM, et al. Biological, clinical and population relevance of 95 loci for blood lipids.
Nature. 2010; 466:707–713. [PubMed: 20686565]
17. International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants
in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;
478:103–109. [PubMed: 21909115]
18. Voight BF, et al. Twelve type 2 diabetes susceptibility loci identified through large scale
association analysis. Nat. Genet. 2010; 42:579–589. [PubMed: 20581827]
19. Dupuis J, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on
type 2 diabetes risk. Nat. Genet. 2010; 42:105–116. [PubMed: 20081858]
20. Speliotes EK, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with
body mass index. Nat. Genet. 2010; 42:937–948. [PubMed: 20935630]
21. Yang J, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies
additional variants influencing complex traits. Nat. Genet. 2012; 44:369–375. [PubMed:
22426310]
22. Ken-Dror G, Talmud PJ, Humphries SE, Dreno F. APOE/C1/C4/C2 gene cluster genotypes,
haplotypes and lipid levels in prospective coronary heart disease risk among UK healthy men.
Mol. Med. 2010; 16:389–399. [PubMed: 20498921]
23. Reilly MP, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and
association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two
genome-wide association studies. Lancet. 2011; 377:383–392. [PubMed: 21239051]
24. Heid IM, et al. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals
sexual dimorphism in the genetic basis of fat distribution. Nat. Genet. 2010; 42:949–960.
[PubMed: 20935629]
25. Storey JD, Tibshirani R. Statistical methods for identifying differentially expressed genes in DNA
microarrays. Methods Mol. Biol. 2003; 224:149–157. [PubMed: 12710672]
26. Hansson GK, Libby P, Schönbeck U, Yan Z-Q. Innate and adaptive immunity in the pathogenesis
of atherosclerosis. Circ. Res. 2002; 91:281–291. [PubMed: 12193460]
27. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific
death. N. Engl. J. Med. 2011; 364:829–841. [PubMed: 21366474]
28. Mozaffarian D, et al. Incidence of new-onset diabetes and impaired fasting glucose in patients with
recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet. 2007;
370:667–675. [PubMed: 17720018]
Page 17
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
29. Turnbull FM, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes.
Diabetologia. 2009; 52:2288–2298. [PubMed: 19655124]
30. Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J. 1999; 138:S419–S420. [PubMed:
10539839]
31. Folkersen L, et al. Association of genetic risk variants with expression of proximal genes identifies
novel susceptibility genes for cardiovascular disease. Circ. Cardiovasc. Genet. 2010; 3:365–373.
[PubMed: 20562444]
32. Grundberg E, et al. Mapping cis- and trans-regulatory effects across multiple tissues in twins: the
MuTHER Study. Nat. Genet. 2012; 44:1084–1089. [PubMed: 22941192]
33. Schadt EE, et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol.
2008; 6:e107. [PubMed: 18462017]
34. Ge B, et al. Global patterns of cis variation in human cells revealed by high-density allelic
expression analysis. Nat. Genet. 2009; 41:1216–1222. [PubMed: 19838192]
Page 18
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Canonical pathway analysis. (a) The four most significant canonical pathways represented in
networks 3, 5 and 9, and overlapping networks ON1 (includes networks 1, 2, 6 and 8) and
ON2 (includes networks 4 and 7); all molecules are listed by network in supplementary table
10. (b) Schematic showing parts of the atherosclerosis signaling, LXR/RXR activation and
acute phase response signaling canonical pathways (Ingenuity) that are involved in both
lipid metabolism and inflammation. Genes in confirmed CAD susceptibility loci (including
both previously and newly reported) and in loci showing suggestive association with an
FDR of <10% are depicted as black and gray ovals, respectively. Other key genes are
depicted as white ovals; notably, some of them, such as IL1F10-IL1B, STAT3 and
HMGCR, have SNPs ranking in the top 1,000 in the FDR analysis. The process leading to
myocardial infarction involves multiple cell types that are depicted in this schematic as a
composite cell (large oval) and its nucleus (inner oval) in the extracellular space; the smooth
muscle cell is shown separately (SMC; red oval), whereas the blue oval depicts cell types
involved in the inflammatory response.
Page 19
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Page 20
Ta
bl
e 
1
A
ss
oc
ia
tio
n 
fin
di
ng
s f
or
 k
no
w
n 
CA
D
 su
sc
ep
tib
ili
ty
 lo
ci
K
no
w
n 
lo
ci
a
Pu
bl
ish
ed
 le
ad
 S
N
P 
or
 p
ro
xy
N
ew
 S
N
P
(r2
 
w
ith
 le
ad
 S
N
P)
C
hr
.
Ef
fe
ct
/n
on
-e
ffe
ct
a
lle
le
 (f
re
qu
en
cy
)
St
ag
e 2
 O
R
St
ag
e 2
 P
C
om
bi
ne
d 
P
C
om
bi
ne
d 
O
R
SO
RT
1b
rs
60
26
33
(ta
gg
ing
 rs
59
98
39
;r2
 
=
 1
.0
0)
1
C/
A
 (0
.77
)
1.
13
2.
19
 ×
 1
0−
18
1.
47
 ×
 1
0−
25
1.
12
PC
SK
9
rs
11
20
65
10
1
T/
C 
(0.
84
)
1.
04
5.
09
 ×
 1
0−
3
1.
79
 ×
 1
0−
5
1.
06
W
D
R1
2
rs
67
25
88
7
2
C/
T 
(0.
11
)
1.
10
5.
29
 ×
 1
0-
8
1.
16
 ×
 1
0−
15
1.
12
M
RA
S
rs
98
18
87
0
3
T/
C 
(0.
14
)
1.
05
1.
83
 ×
 1
0−
3
2.
62
 ×
 1
0−
9
1.
07
TC
F2
1
rs
12
19
02
87
6
C/
G
 (0
.59
)
1.
04
6.
48
 ×
 1
0−
4
4.
94
 ×
 1
0−
13
1.
07
SL
C2
2A
3-
LP
AL
2-
LP
A
rs
37
98
22
0
6
C/
T 
(0.
01
)
1.
28
4.
90
 ×
 1
0−
5
N
/A
N
/A
rs
20
48
32
7 
(0.
03
)
6
G
/A
 (0
.35
)
1.
05
1.
09
 ×
 1
0−
5
6.
86
 ×
 1
0−
11
1.
06
ZC
3H
C1
rs
11
55
69
24
7
C/
T 
(0.
65
)
1.
08
1.
45
 ×
 1
0−
9
6.
74
 ×
 1
0−
17
1.
09
CD
KN
2B
AS
1
rs
13
33
04
9
9
C/
G
 (0
.47
)
1.
21
1.
08
 ×
 1
0−
34
1.
39
 ×
 1
0−
52
1.
23
rs
32
17
99
2 
(0.
50
)
9
A
/G
 (0
.38
)
1.
14
7.
27
 ×
 1
0−
32
7.
75
 ×
 1
0−
57
1.
16
A
BO
rs
57
94
59
9
C/
T 
(0.
21
)
1.
04
2.
13
 ×
 1
0−
2
2.
66
 ×
 1
0−
8
1.
07
CY
P1
7A
1-
CN
NM
2-
NT
5C
2
rs
12
41
34
09
10
G
/A
 (0
.89
)
1.
08
4.
12
 ×
 1
0−
3
6.
26
 ×
 1
0−
8
1.
10
K
IA
A
14
62
rs
25
05
08
3
10
C/
T 
(0.
42
)
1.
06
2.
82
 ×
 1
0−
7
1.
35
 ×
 1
0−
11
1.
06
PD
GF
D
rs
97
48
19
11
A
/G
 (0
.29
)
1.
08
2.
03
 ×
 1
0−
9
3.
55
 ×
 1
0−
11
1.
07
SH
2B
3
rs
31
84
50
4
12
T/
C 
(0.
40
)
1.
07
6.
13
 ×
 1
0−
7
5.
44
 ×
 1
0−
11
1.
07
CO
L4
A1
-C
OL
4A
2
rs
47
73
14
4
13
G
/A
 (0
.42
)
1.
06
2.
34
 ×
 1
0−
6
1.
43
 ×
 1
0−
11
1.
07
rs
95
15
20
3 
(0.
01
)
13
T/
C 
(0.
74
)
1.
08
1.
13
 ×
 1
0−
8
5.
85
 ×
 1
0−
12
1.
08
H
H
IP
L1
rs
28
95
81
1
14
C/
T 
(0.
43
)
1.
04
1.
18
 ×
 1
0−
4
4.
08
 ×
 1
0−
10
1.
06
RA
I1
-P
EM
T-
RA
SD
1
rs
12
93
65
87
17
G
/A
 (0
.59
)
1.
04
2.
06
 ×
 1
0−
4
1.
24
 ×
 1
0−
9
1.
06
LD
LR
rs
11
22
60
8
19
G
/T
 (0
.76
)
1.
06
3.
72
 ×
 1
0−
6
6.
33
 ×
 1
0−
14
1.
10
G
en
e 
de
se
rt 
(K
CN
E2
)
rs
99
82
60
1
21
T/
C 
(0.
13
)
1.
10
8.
69
 ×
 1
0−
9
7.
67
 ×
 1
0−
17
1.
13
PP
A
P2
B
rs
17
11
40
36
1
A
/G
 (0
.91
)
1.
09
2.
68
 ×
 1
0−
5
5.
80
 ×
 1
0−
12
1.
11
A
N
K
S1
A
rs
12
20
53
31
 (t
ag
gin
g r
s1
76
09
94
0; 
r2
 
=
 0
.8
5)
6
C/
T 
(0.
81
)
1.
01
4.
36
 ×
 1
0-
1
4.
18
 ×
 1
0−
5
1.
04
PH
A
CT
R1
rs
93
69
64
0 
(ta
gg
ing
 rs
12
52
64
53
;
r2
 
=
 0
.9
0)
6
A
/C
 (0
.65
)
1.
09
1.
11
 ×
 1
0-
12
7.
53
 ×
 1
0−
22
1.
09
CX
CL
12
rs
50
11
20
10
A
/G
 (0
.83
)
1.
06
7.
13
 ×
 1
0−
5
1.
79
 ×
 1
0−
9
1.
07
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Page 21
K
no
w
n 
lo
ci
a
Pu
bl
ish
ed
 le
ad
 S
N
P 
or
 p
ro
xy
N
ew
 S
N
P
(r2
 
w
ith
 le
ad
 S
N
P)
C
hr
.
Ef
fe
ct
/n
on
-e
ffe
ct
a
lle
le
 (f
re
qu
en
cy
)
St
ag
e 2
 O
R
St
ag
e 2
 P
C
om
bi
ne
d 
P
C
om
bi
ne
d 
O
R
rs
20
47
00
9 
(0.
05
)
10
C/
A
 (0
.48
)
1.
05
9.
66
 ×
 1
0−
6
1.
59
 ×
 1
0−
9
1.
05
LI
PA
rs
22
46
83
3
(ta
gg
ing
 rs
14
12
44
4; 
r2
 
=
 0
.9
8)
10
T/
C 
(0.
38
)
1.
04
2.
76
 ×
 1
0−
2
9.
49
 ×
 1
0−
6
1.
06
rs
11
20
30
42
 (0
.39
)
10
T/
C 
(0.
44
)
1.
03
9.
86
 ×
 1
0−
3
6.
08
 ×
 1
0−
6
1.
04
U
BE
2Z
rs
15
56
3 
(ta
gg
ing
 rs
46
52
2;
r2
 
=
 0
.9
3)
17
C/
T 
(0.
52
)
1.
01
2.
44
 ×
 1
0-
1
9.
37
 ×
 1
0−
6
1.
04
SM
G6
rs
22
81
72
7
(ta
gg
ing
 rs
21
61
72
; r
2  
=
 0
.9
6)
17
C/
T 
(0.
36
)
1.
04
8.
46
 ×
 1
0−
4
7.
83
 ×
 1
0−
9
1.
05
A
po
E-
A
po
C1
rs
20
75
65
0
19
G
/A
 (0
.14
)
1.
11
5.
86
 ×
 1
0-
11
N
/A
N
/A
rs
44
59
25
 (0
.03
)
19
C/
T 
(0.
90
)
1.
13
8.
76
 ×
 1
0−
9
N
/A
N
/A
M
IA
3
N
/A
rs
17
46
48
57
 (0
.18
)
1
T/
G
 (0
.87
)
1.
02
1.
56
 ×
 1
0-
1
6.
06
 ×
 1
0−
5
1.
05
7q
22
N
/A
rs
12
53
98
95
 (0
.64
)
7
A
/C
 (0
.19
)
1.
02
4.
00
 ×
 1
0−
2
5.
33
 ×
 1
0−
4
1.
08
ZN
F2
59
-A
PO
A5
-A
PO
A1
N
/A
rs
93
26
24
6 
(0.
63
)
11
C/
G
 (0
.10
)
1.
04
2.
90
 ×
 1
0−
2
1.
51
 ×
 1
0−
7
1.
09
A
D
A
M
TS
7
N
/A
rs
71
73
74
3 
(0.
38
)
15
T/
C 
(0.
58
)
1.
06
2.
46
 ×
 1
0−
7
6.
74
 ×
 1
0−
13
1.
07
Ch
r.,
 c
nr
om
os
om
e.
a L
oc
us
 C
6o
rf1
05
,
 
w
hi
ch
 h
as
 b
ee
n 
re
po
rte
d 
on
ly
 in
 C
hi
ne
se
 a
nd
 h
as
 n
o 
go
od
 p
ro
xy
 S
N
P 
(U
tah
 re
sid
en
ts 
of 
No
rth
ern
 an
d W
est
ern
 E
uro
pe
an
 an
ce
str
y (
CE
U)
 or
 H
an
 C
hin
ese
 in
 B
eij
ing
, C
hin
a (
CH
B)
) o
n t
he
M
et
ab
oc
hi
p.
 T
he
 b
es
t a
va
ila
bl
e 
pr
ox
y 
is 
rs
93
48
95
3 
(r2
 
=
 0
.0
1),
 w
ith
 co
mb
ine
d P
 
=
 2
.8
1 
× 
10
−
3 .
b r
s1
27
40
37
4,
 w
hi
ch
 w
as
 re
po
rte
d 
as
 a
 fu
nc
tio
na
l v
ar
ia
nt
 in
 th
is 
lo
cu
s a
nd
 h
as
 r2
 
=
 0
.8
95
 w
ith
 rs
59
98
39
, h
as
 co
m
bi
ne
d 
P 
=
 8
.2
5 
× 
10
−
18
 
(O
R 
= 1
.13
5) 
ba
sed
 on
 th
e r
an
do
m-
eff
ec
ts 
mo
de
l u
sed
 (P
 
in
 st
ag
e 
2
al
on
e 
w
as
 6
.4
8 
× 
10
−
21
 
u
n
de
r t
he
 fi
xe
d-
ef
fe
ct
 m
od
el
).
Nat Genet. Author manuscript; available in PMC 2013 June 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Page 22
Ta
bl
e 
2
A
dd
iti
on
al
 lo
ci
 sh
ow
in
g 
ge
no
m
e-
w
id
e 
sig
ni
fic
an
t a
ss
oc
ia
tio
n 
w
ith
 C
A
D
St
ag
e 1
 (1
8,0
14
ca
se
s 
a
n
d 
40
,9
25
 
co
n
tr
ol
s)a
St
ag
e 2
 (4
0,3
65
ca
se
s 
a
n
d 
63
,7
14
 
co
n
tr
ol
s)
C
om
bi
ne
d
(st
ag
es 
1
 
a
n
d 
2)
St
ag
e 3
 (5
,05
5
ca
se
s 
a
n
d 
5,
61
7
 
co
n
tr
ol
s)
C
om
bi
ne
d
(st
ag
es 
1–
3)
SN
P
C
hr
.
N
ea
re
st
 g
en
e(s
)
Ef
fe
ct
/n
on
-
ef
fe
ct
 a
lle
le
(fr
eq
ue
nc
y)
O
R
P
O
R
P
P
O
R
P
P
Bi
ol
og
ic
al
re
le
va
nc
eb
N
ew
rs
48
45
62
5
1
IL
6R
T/
C 
(0.
47
)
1.
06
4.
84
 ×
 1
0−
5
1.
04
3.
46
 ×
 1
0−
5
3.
55
 ×
 1
0−
8
1.
09
1.
58
 ×
 1
0−
3
3.
64
 ×
 1
0−
10
2
rs
51
51
35
2
A
PO
B
G
/A
 (0
.83
)
1.
07
8.
63
 ×
 1
0−
4
1.
08
2.
17
 ×
 1
0−
8
4.
80
 ×
 1
0−
10
1.
03
4.
02
 ×
 1
0−
1
2.
56
 ×
 1
0−
10
1
rs
22
52
64
1
2
ZE
B2
-A
C0
74
09
3.
1
G
/A
 (0
.46
)
1.
06
1.
37
 ×
 1
0−
5
1.
04
1.
27
 ×
 1
0−
4
3.
66
 ×
 1
0−
8
1.
00
9.
54
 ×
 1
0−
1
5.
30
 ×
 1
0−
8
rs
15
61
19
8
2
V
A
M
P5
-V
AM
P8
-G
GC
X
A
/G
 (0
.45
)
1.
06
7.
47
 ×
 1
0−
5
1.
05
2.
57
 ×
 1
0−
6
4.
48
 ×
 1
0−
9
1.
07
1.
75
 ×
 1
0−
2
1.
22
 ×
 1
0−
10
A
,1
rs
76
92
38
7
4
GU
CY
1A
3
G
/A
 (0
.81
)
1.
08
1.
04
 ×
 1
0−
5
1.
06
1.
89
 ×
 1
0−
5
4.
57
 ×
 1
0−
9
1.
13
5.
47
 ×
 1
0−
4
2.
65
 ×
 1
0−
11
1
rs
27
39
09
5
SL
C2
2A
4-
SL
C2
2A
5
C/
T 
(0.
14
)
1.
07
3.
24
 ×
 1
0−
3
1.
09
2.
00
 ×
 1
0−
7
1.
43
 ×
 1
0−
8
1.
11
2.
43
 ×
 1
0−
2
9.
62
 ×
 1
0−
10
A
,1
rs
10
94
77
89
6
K
CN
K5
T/
C 
(0.
76
)
1.
07
6.
07
 ×
 1
0−
5
1.
06
1.
22
 ×
 1
0−
5
1.
63
 ×
 1
0−
8
1.
01
7.
03
 ×
 1
0−
1
9.
81
 ×
 1
0−
9
3
rs
42
52
12
0
6
PL
G
T/
C 
(0.
73
)
1.
07
1.
18
 ×
 1
0−
5
1.
06
1.
82
 ×
 1
0−
5
5.
00
 ×
 1
0−
9
1.
07
9.
58
 ×
 1
0−
2
4.
88
 ×
 1
0−
10
1
rs
26
4
8
LP
L
G
/A
 (0
.86
)
1.
11
2.
99
 ×
 1
0−
7
1.
05
7.
30
 ×
 1
0−
4
5.
06
 ×
 1
0−
9
1.
06
1.
60
 ×
 1
0−
1
2.
88
 ×
 1
0−
9
1
rs
93
19
42
8
13
FL
T1
A
/G
 (0
.32
)
1.
06
7.
88
 ×
 1
0−
5
1.
05
5.
70
 ×
 1
0−
6
1.
01
 ×
 1
0−
8
1.
10
1.
37
 ×
 1
0−
3
7.
32
 ×
 1
0−
11
1
rs
17
51
48
46
15
FU
RI
N
-F
ES
A
/C
 (0
.44
)
1.
07
2.
37
 ×
 1
0−
5
1.
05
7.
35
 ×
 1
0−
7
4.
49
 ×
 1
0−
10
1.
04
3.
02
 ×
 1
0−
1
9.
33
 ×
 1
0−
11
A
,1
Pr
ev
io
us
lv
 r
ep
or
te
d 
at
 a
rr
ay
-w
id
e 
le
ve
l o
f s
ig
ni
fic
an
ce
 (P
 
<
 3
 ×
 1
0−
6 )
R
s2
95
40
29
8
TR
IB
1
A
/T
 (0
.55
)
1.
06
2.
79
 ×
 1
0−
5
1.
04
7.
75
 ×
 1
0−
5
4.
53
 ×
 1
0−
8
1.
05
8.
56
 ×
 1
0−
2
4.
75
 ×
 1
0−
9
4
R
s6
54
47
13
2
A
BC
G5
-A
BC
G8
T/
C 
(0.
30
)
1.
06
2.
22
 ×
 1
0−
4
1.
06
1.
57
 ×
 1
0−
7
8.
72
 ×
 1
0−
10
0.
96
3.
56
 ×
 1
0−
1
2.
12
 ×
 1
0−
9
1
N
ew
 (s
tag
e 3
 re
pli
ca
tio
n)
R
s1
87
84
06
4
ED
N
RA
T/
C 
(0.
15
)
1.
10
2.
37
 ×
 1
0−
6
1.
06
3.
54
 ×
 1
0−
3
1.
65
 ×
 1
0−
7
1.
09
2.
01
 ×
 1
0−
2
2.
54
 ×
 1
0−
8
1
R
s2
02
39
38
7
H
D
A
C9
G
/A
 (0
.10
)
1.
08
6.
81
 ×
 1
0−
4
1.
07
5.
25
 ×
 1
0−
5
6.
49
 ×
 1
0−
7
1.
13
4.
09
 ×
 1
0−
2
4.
94
 ×
 1
0−
8
1
a T
ot
al
 sa
m
pl
e 
siz
es
 d
o 
no
t i
nc
lu
de
 th
e 
CH
A
RG
E 
sa
m
pl
e 
siz
es
.
b A
, c
is 
eQ
TL
 in
 L
CL
s; 
1, 
mo
us
e m
od
el 
av
ail
ab
le 
wi
th 
ca
rdi
ov
asc
ula
r p
he
no
typ
e; 
2, 
mo
us
e m
od
el 
ha
s h
om
eo
sta
tic
 an
d i
mm
un
e p
he
no
typ
es;
 3,
 m
ou
se 
mo
de
l h
as 
res
pir
ato
ry,
 ne
rvo
us
 sy
ste
m,
 m
ort
ali
ty,
ag
in
g,
 g
ro
w
th
 a
nd
 re
na
l p
he
no
ty
pe
s; 
4,
 m
ou
se
 m
od
el
 h
as
 g
ro
w
th
 a
nd
 im
m
un
e 
ph
en
ot
yp
es
.
Nat Genet. Author manuscript; available in PMC 2013 June 12.
